Literature DB >> 22266884

Genetics of the dominant ataxias.

Dineke S Verbeek1, Bart P C van de Warrenburg.   

Abstract

The relevant clinical, genetic, and cell biologic aspects of the dominantly inherited spinocerebellar ataxias (SCAs) are reviewed in this article. SCAs are diseases of the entire nervous system; in addition to cerebellar ataxia, the central (but not obligate) disease feature, many noncerebellar complications can be present as well. There are over 35 genetic subtypes: although those caused by expanded CAG repeats are still the more common ones, the majority of the recent SCAs have been caused by more conventional mutations. Genotype-phenotype correlations do exist and are most clear for the repeat expansion, where repeat length partially explains age at onset, disease severity and progression, and the core clinical phenotype. Some common themes within the disease mechanisms seem to emerge, including misfolding and aggregation, impairment of the protein quality control system, abnormal protein interactions, disruption of gene transcription, RNA toxicity, and changes in glutamate and calcium signaling. Yet despite this exciting progress in the molecular genetic background and suggested corresponding pathways, there is still no drug available that is specifically designed for or targeted at the mechanisms at play. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266884     DOI: 10.1055/s-0031-1299785

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  13 in total

1.  [Development of neurology in Germany after 1960].

Authors:  J Dichgans
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

Review 2.  Recent advances in clinical neurogenetics.

Authors:  José Berciano
Journal:  J Neurol       Date:  2012-11-16       Impact factor: 4.849

Review 3.  How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?

Authors:  Marka van Blitterswijk; Mariely DeJesus-Hernandez; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2012-12       Impact factor: 5.710

4.  A conserved eEF2 coding variant in SCA26 leads to loss of translational fidelity and increased susceptibility to proteostatic insult.

Authors:  Katherine E Hekman; Guo-Yun Yu; Christopher D Brown; Haipeng Zhu; Xiaofei Du; Kristina Gervin; Dag Erik Undlien; April Peterson; Giovanni Stevanin; H Brent Clark; Stefan M Pulst; Thomas D Bird; Kevin P White; Christopher M Gomez
Journal:  Hum Mol Genet       Date:  2012-09-21       Impact factor: 6.150

Review 5.  Recent advances in the genetic etiology of brain malformations.

Authors:  David A Dyment; Sarah L Sawyer; Jodi Warman Chardon; Kym M Boycott
Journal:  Curr Neurol Neurosci Rep       Date:  2013-08       Impact factor: 5.081

Review 6.  [Ataxias and hereditary spastic paraplegias].

Authors:  R Schüle; L Schöls
Journal:  Nervenarzt       Date:  2017-07       Impact factor: 1.214

7.  Altered Purkinje cell miRNA expression and SCA1 pathogenesis.

Authors:  Edgardo Rodriguez-Lebron; Gumei Liu; Megan Keiser; Mark A Behlke; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2013-01-30       Impact factor: 5.996

Review 8.  DNA repair abnormalities leading to ataxia: shared neurological phenotypes and risk factors.

Authors:  Edward C Gilmore
Journal:  Neurogenetics       Date:  2014-07-20       Impact factor: 2.660

9.  Phenotypic and Genotypic Analysis of Hereditary Ataxia Patients in Sakarya City, Turkey.

Authors:  Saadet Sayan; Dilcan Kotan; Aslı Gündoğdu-Eken; Irmak Şahbaz; Cemile Koçoğlu; A Nazlı Başak
Journal:  Noro Psikiyatr Ars       Date:  2018-07-11       Impact factor: 1.339

10.  Mapping the self-association domains of ataxin-1: identification of novel non overlapping motifs.

Authors:  Rajesh P Menon; Daniel Soong; Cesira de Chiara; Mark Holt; John E McCormick; Narayana Anilkumar; Annalisa Pastore
Journal:  PeerJ       Date:  2014-03-25       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.